Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

K B Gordon, A B Kimball, D Chau, H N Viswanathan, J Li, D A Revicki, G Kricorian, B G Ortmeier, K B Gordon, A B Kimball, D Chau, H N Viswanathan, J Li, D A Revicki, G Kricorian, B G Ortmeier

Abstract

Background: Psoriasis symptoms have a significant negative impact on health-related quality of life, impairing physical functioning and well-being.

Objective: To evaluate the impact of brodalumab, a human anti-interleukin-17R monoclonal antibody, on psoriasis symptom severity as measured by a novel patient-reported outcome measure, the Psoriasis Symptom Inventory, and dermatology-specific health-related quality of life as measured by the Dermatology Life Quality Index (DLQI).

Methods: This was a secondary analysis of a phase II, randomized, double-blind, placebo-controlled clinical study of patients with moderate-to-severe psoriasis (n = 198) treated with brodalumab or placebo. This analysis assessed Psoriasis Symptom Inventory scores and DLQI scores over time. Analyses were conducted on all patients who were randomized and received one or more injections of the study drug according to intention to treat using last observation carried forward to impute missing data.

Results: At week 12, subjects in the brodalumab groups had significant improvements in mean Psoriasis Symptom Inventory total scores [8.5 (70 mg), 15.8 (140 mg), 16.2 (210 mg) and 12.7 (280 mg)] compared with placebo (4.8). Mean improvements in DLQI were clinically meaningful (≥ 5.7) in the brodalumab groups (6.2, 9.1, 9.6 and 7.1, respectively) and significantly greater than placebo (3.1). Improvements in Psoriasis Symptom Inventory were observed as early as week 2 and in DLQI by week 4. All eight Psoriasis Symptom Inventory item scores improved significantly among the brodalumab groups by week 12.

Conclusions: Results were from a single randomized clinical trial and may not generalize to broader patient populations. However, treatment with brodalumab provided significant improvement in psoriasis symptoms in patients with moderate-to-severe psoriasis.

Trial registration: ClinicalTrials.gov NCT00975637.

© 2013 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Figures

Fig 1
Fig 1
Mean Psoriasis Symptom Inventory (7-day) and Dermatology Life Quality Index (DLQI) total scores over time. (a) Mean (SD) Psoriasis Symptom Inventory total score by treatment group: brodalumab 70 mg every 2 weeks (Q2W) arm (P < 0·005), 140- and 210-mg Q2W arms (P < 0·0001) and 280 mg every 4 weeks (Q4W) arms (P < 0·0001) at week 2 to week 12. (b) Mean (SD) DLQI total score by treatment group. (c) Mean (SD) improvement in Psoriasis Symptom Inventory total score, DLQI total score and Psoriasis Area and Severity Index (PASI) score for the 140-mg brodalumab group.
Fig 2
Fig 2
Mean (SD) Psoriasis Symptom Inventory (7-day) item scores over time. Itch (P ≤ 0·002), burning (P ≤ 0·002), redness (P ≤ 0·0009), scaling (P ≤ 0·0001), flaking (P < 0·0004), cracking (P < 0·0004), stinging (P < 0·02) and pain (P ≤ 0·0008) at week 2 to week 12. Q2W, every 2 weeks; Q4W, every 4 weeks.
Fig 3
Fig 3
Proportion of subjects achieving Psoriasis Symptom Inventory (7-day) score of 0 over time for the 140-mg brodalumab group. 5-point Likert-type scale: 0, no symptoms; 4, severe symptoms.
Fig 4
Fig 4
Dermatology Life Quality Index (DLQI) domain scores over time. Q2W, every 2 weeks; Q4W, every 4 weeks.
Fig 5
Fig 5
Proportion of subjects with a complete or almost complete response at week 12. (a) Proportion of subjects with a Psoriasis Symptom Inventory total score of 0 at week 12. (b) Proportion of subjects with a Dermatology Life Quality Index (DLQI) score of 0 or 1. Q2W, every 2 weeks; Q4W, every 4 weeks.

References

    1. Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol. 2007;156:1346–9.
    1. Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol. 2000;143:969–73.
    1. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35.
    1. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122:602–7.
    1. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9.
    1. National Psoriasis Foundation. 2008. Survey panel snapshot, Available from: (last accessed 28 October 2013)
    1. Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260–70.
    1. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25–31.
    1. Marquis P, Arnould B, Acquadro C, Roberts WM. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Dev Res. 2006;67:193–201.
    1. Otuki MF, Reis RC, Cabrini D. Patient-reported outcomes in psoriasis research and practice. Br J Dermatol. 2011;165:1361–2.
    1. Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
    1. Martin ML, McCarrier K, Bushnell DM, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient reported outcome measure. Presented at the 20th European Academy of Dermatology and Venereology Congress, Lisbon, Portugal, 20–24 October 2011.
    1. Martin ML, McCarrier K, Chiou C-F, et al. Development of a new patient reported measure for assessing symptoms of psoriiasis. J Am Acad Dermatol. 2012;66(Suppl.1):AB 190.
    1. Martin ML, McCarrier K, Bushnell DM, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure. J Am Acad Dermatol. 2012;66(Suppl. 1):AB 207.
    1. Bushnell DM, Martin ML, McCarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24:356–60.
    1. Revicki DA, Jin Y, Wilson HD, et al. Reliability and validity of the Psoriasis Symptom Inventory in patients with moderate to severe psoriasis. J Dermatolog Treat. 2013 Jun 11 [Epub ahead of print]
    1. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–16.
    1. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe